[1]
|
Esenwa C, Gutierrez J. Secondary stroke prevention:challenges and solutions[J]. Vasc Health Risk Manag, 2015, 11:437-450. http://pubmedcentralcanada.ca/pmcc/articles/PMC4536764/ |
[2]
|
Lee PN, Thornton AJ, Forey BA, et al. Environmental Tobacco Smoke Exposure and Risk of Stroke in Never Smokers:An Updated Review with Meta-Analysis[J]. J Stroke Cerebrovascular Dis, 2017, 26:204-216. doi: 10.1016/j.jstrokecerebrovasdis.2016.09.011 |
[3]
|
SPSS3 Study Group, Benavente OR, Coffey CS, et al. Blood-pressure targets in patients with recent lacunar stroke:the SPS3 randomised trial[J]. Lancet, 2013, 382:507-515. doi: 10.1016/S0140-6736(13)60852-1 |
[4]
|
Lin MP, Ovbiagele B, Markovic D, et al. Association of Secondhand Smoke with Stroke Outcomes[J]. Stroke, 2016, 47:2828-2835. doi: 10.1161/STROKEAHA.116.014099 |
[5]
|
Fu J, Tang J, Yang J, et al. Adding computed tomography and transcranial Doppler findings to the ABCD2 score to predict long-term risk of stroke after transient ischaemic attack or minor stroke[J]. Eur J Neurol, 2015, 22:520-526. doi: 10.1111/ene.12606 |
[6]
|
Chadha DS, Sumana B, Karthikeyan G, et al. Prevalence of aspirin resistance in Asian-Indian patients with stable coronary artery disease[J]. Catheter Cardiovasc Interv, 2016, 88:E126-E131. doi: 10.1002/ccd.25420 |
[7]
|
Jia DM, Chen ZB, Zhang MJ, et al. CYP2C19 polymor-phisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China[J]. Stroke, 2013, 44:1717-1719. doi: 10.1161/STROKEAHA.113.000823 |
[8]
|
Cattaneo M, Cerletti C, Harrison P, et al. Recommendations for the Standardization of Light Transmission Aggregometry:A Consensus of the Working Party from the Platelet Physiology Subcommittee of SSC/ISTH[J]. J Thromb Haemost, 2013, 11:1183-1189. doi: 10.1111/jth.12231 |
[9]
|
Chen HY, Chou P. PFA-100-measured aspirin resistance is the predominant risk factor for hospitalized cardiovascular events in aspirin-treated patients:A 5-year cohort study[J]. J Clin Pharm Ther, 2018, 43:249-255. doi: 10.1111/jcpt.12643 |
[10]
|
Quarterman C, Shaw M, Johnson I, et al. Intra- and inter-centre standardisation of thromboelastography (TEG®)[J]. Anaesthesia, 2014, 69:883-890. doi: 10.1111/anae.12748 |
[11]
|
Fu Z, Dong W, Shen M, et al. Relationship between hyporesponsiveness to clopidogrel measured by thrombelastography and in stent restenosis in patients undergoing percutaneous coronary intervention[J]. Clin Biochem, 2014, 47:197-202. doi: 10.1016/j.clinbiochem.2014.08.009 |
[12]
|
Lin YJ, Li JW, Zhang MJ, et al. The association between CYP2C19 genotype and of in-stent restenosis among patients with vertebral artery stent treatment[J]. CNS Neurosci Ther, 2014, 20:125-130. doi: 10.1111/cns.12173 |
[13]
|
Pan Y, Chen W, Xu Y, et al. Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack:A Systematic Review and Meta-Analysis[J]. Circulation, 2017, 135:21-33. doi: 10.1161/CIRCULATIONAHA.116.024913 |
[14]
|
Wang Y, Zhao X, Lin J, et al. Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack[J]. JAMA, 2016, 316:70-78. doi: 10.1001/jama.2016.8662 |
[15]
|
Anderson CD, Biffi A, Greenberg SM, et al. Personalized approaches to clopidogrel therapy:are we there yet?[J].Stroke, 2010, 41:2997-3002. doi: 10.1161/STROKEAHA.110.594069 |